Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UA021 in moderate to severe plaque psoriasis
NCT07234591Phase 2Recruiting
- Sponsor
- Usynova Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of UA021 in plaque psoriasis, sponsored by Usynova Pharmaceuticals. Started Oct 2025; status: recruiting.
02
Drugs
UA021
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07234591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07234591.